Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multi-omics profiling uncovers immune-molecular clusters with distinct chemo-immunotherapeutic vulnerabilities in a mouse model of triple-negative breast cancer

ABSTRACT: Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous subtype of breast cancer with limited treatment options. Predicting patient response to chemo-immunotherapy remains challenging, highlighting the need for stratification. Here, we performed an integrative multi-parametric analysis combining histological, genomic, transcriptomic, proteomic, and immune profiling in the immunocompetent MMTV-R26Met TNBC mouse model and matched outcomes with patient data. We uncovered four distinct TNBC clusters defined by unique intrinsic (molecular/genomic) and extrinsic (immune) features that closely parallel patient subtypes. We established syngeneic graft models faithfully recapitulating both molecular and immune hallmarks of primary tumors, emphasizing their translational relevance. Strikingly, in vivo evaluation of combined chemotherapy (epirubicin) and anti-PD-1 immunotherapy revealed cluster-specific therapeutic vulnerabilities associated with molecular and immune traits. Findings document how TNBC response is shaped by both tumor-intrinsic and immune features. Our study provides a robust preclinical platform for precision immuno-oncology, enabling stratification of TNBC patients for tailored onco-immunotherapies.

ORGANISM(S): Mus musculus

PROVIDER: GSE310100 | GEO | 2026/01/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Breast cancer-subtype and infiltrating macrophage signatures predict chemotherapy-response and survival

Project description:Triple-Negative Breast Cancer (TNBC) is a heterogeneous collection of cancers where personalized treatment is difficult and chemotherapy and immunotherapy combinations are the main treatment options. Many attempts to tackle patient heterogeneity have focused on defining cancer-intrinsic subtypes based on differential tumor mRNA-expression across patient cohorts. While these multi-gene diagnostics have shown success in hormone receptor- positive cancers (e.g. OncotypeDX), no TNBC classifiers have shown clinical utility in predicting patient survival or treatment response. We hypothesize that TNBC-infiltrating immune-cells both affect mRNA-based classification and contribute to treatment response variability. To evaluate this hypothesis, we benchmarked the performance of common TNBC-classification (TNBC-type) and infiltrating immune (CIBERSORT) algorithms on the same underlying datasets. Encouragingly, we found that – as with OncotypeDx– highly proliferative TNBC-subtypes (BL1) show the strongest evidence of response to cytotoxic chemotherapies. Interestingly, this cancer-proliferative signature (BL1) is strongly correlated with enrichment in tumor-infiltrating lymphocyte signatures (TIL) which show superior prognostic and predictive power. In addition, Tumor Associated Macrophage (TAM) signatures show independent predictive and prognostic power for both patient survival and response to anthracycline- and taxane-based chemotherapies. These gene signature-based correlations were validated in a new independent cohort of 67 TNBC-patients treated with neoadjuvant chemotherapy. Overall, these results argue for the independent contributions of both cancer-intrinsic and -extrinsic factors in predicting treatment response in the neoadjuvant setting.

2024-03-20 | GSE260693 | GEO

Breast cancer stem cell-derived tumors escape from γδ T cell immunosurveillance in vivo by modulating γδ T cell ligands

Project description:Triple negative breast cancer (TNBC) lacks targeted therapy options. TNBC is enriched in breast cancer stem cells (BCSCs), which play a key role in metastasis, chemoresistance, relapse and mortality. γδ T cells hold great potential in immunotherapy against cancer, and might be an alternative to target TNBC. γδ T cells are commonly observed to infiltrate solid tumors and have an extensive repertoire of tumor sensing, recognizing stress-induced molecules and phosphoantigens (pAgs) on transformed cells. We show that patient derived triple negative BCSCs are efficiently recognized and killed by ex vivo expanded γδ T cells from healthy donors. Orthotopically xenografted BCSCs, however, were refractory to γδ T cell immunotherapy. Mechanistically, we unraveled concerted differentiation and immune escape: xenografted BCSCs lost stemness, expression of γδ T cell ligands, adhesion molecules and pAgs, thereby evading immune recognition by γδ T cells. Indeed, neither pro-migratory engineered γδ T cells, nor anti-PD 1 checkpoint blockade significantly prolonged overall survival of tumor-bearing mice. BCSC immune escape was independent of the immune pressure exerted by the γδ T cells, and could be pharmacologically reverted by Zoledronate or IFN-α treatment. These results pave the way for novel combinatorial immunotherapies for TNBC.

2023-07-20 | PXD039463 | Pride

Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies

Project description:Triple-negative breast cancer (TNBC) is the most heterogeneous and aggressive subtype of breast carcinoma, defined by the absence of clinical biomarkers and the lack of targeted therapies. Despite numerous clinical trials, patient stratification remains suboptimal, limiting the identification of effective treatment strategies. In this study, we aimed to identify biomarkers exclusively expressed in the basal mammary epithelial compartment to refine TNBC subclassification. Through computational analysis of single-cell RNA sequencing data, we defined a set of basal identity genes, which were subsequently validated by immunohistochemistry in two independent TNBC cohorts. This approach enabled the identification of a novel TNBC subgroup, termed true basal TNBC (tB-TNBC), associated with poorer prognosis and distinct molecular features. To uncover therapeutic vulnerabilities in this subgroup, we conducted a high-throughput screen of 3,200 FDA-approved compounds in breast cancer cell lines classified by basal marker expression. This analysis identified dasatinib as a promising candidate with selective activity against tB-TNBC models. Furthermore, TAGLN emerged as a strong predictive biomarker of dasatinib response, with functional studies confirming its role in modulating drug sensitivity. Altogether, these findings support the clinical utility of basal markers for TNBC stratification and highlight a targeted treatment opportunity for tB-TNBC patients.

2026-02-04 | GSE300385 | GEO

Effect of depletion of ISG20 on gene expression in EMT6 mouse breast cancer cells with RNA-Seq.

Project description:Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the highest rates of recurrence, metastasis and patient mortality due to lack of effective targeted therapies. In this study, we demonstrate that ISG20 expression is induced by hypoxia and directly targeted by HIF-1 for transcription in TNBC cells. ISG20 functions as RNA exonuclease to target mRNAs for degradation, resulting in breast cancer stem cell specification and lung metastasis, and also cancer cell immune evasion. Mostly importantly, ISG20 silencing could markedly increase the sensitivity of TNBC to anti-PD1 immune checkpoint blockade (ICB) in a mouse model. Our data suggested that, in combination with immunotherapy, targeting ISG20 might be an effective strategy for TNBC treatment.

2025-11-25 | GSE287164 | GEO

In vivo epigenetic CRISPR screen identifies Asf1a as an immunotherapeutic target in Kras-mutant lung adenocarcinoma

Project description:Despite substantial progress in lung cancer immunotherapy, the overall response rate in KRAS-mutant lung adenocarcinoma (ADC) patients remains low. Combining standard immunotherapy with adjuvant approaches that enhance adaptive immune responsesâ€”such as epigenetic modulation of anti-tumor immunityâ€”is therefore an attractive strategy. To identify epigenetic regulators of tumor immunity, we constructed an epigenetic-focused sgRNA library, and performed an in vivo CRISPR screen in KrasG12D/P53-/- (KP) lung ADC model. Our data showed that loss of the histone chaperone Asf1a in tumor cells sensitizes tumors to anti-PD-1 treatment. Mechanistic studies revealed that tumor cell intrinsic Asf1a deficiency induced immunogenic macrophage differentiation in the tumor microenvironment by upregulating GM-CSF expression and potentiated T cell activation in combination with anti-PD-1. Our results provide a rationale for a novel combination therapy consisting of Asf1a inhibition and anti-PD-1 immunotherapy.

2019-11-26 | GSE138571 | GEO

Proteomics from Triple-Negative Breast Cancer from the MMTV-R26Met Model

Project description:We have developed the MMTV-R26Met mouse model, which exclusively generates TNBC and recapitulates key features of the human disease in an immunocompetent setting. In this study, we provide a proteomics characterization of MMTV-R26Met-derived tumors. This integrative approach reveals distinct tumor clusters that reflect patient-like heterogeneity and provides a valuable framework for TNBC stratification and therapeutic development.

2026-01-16 | PXD067482 | Pride

A single-cell map of intratumoral heterogeneity during combination treatment of anti-PD1 and chemotherapy in triple-negative breast cancer

Project description:Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC), which exhibited a poor prognosis due to the highly tumor microenvironmental heterogeneity and specific mutations. Recent studies have investigated the different celltypes in TNBC microenvironment, however, the effects of immunotherapy and chemotherapy combination therapy on TNBC are largely unknown. Here we explored the changes of TNBC microenvironment upon immunotherapy and chemotherapy combination therapy by scRNA-seq. We found that the insensitive (PCPAi) patient exhibited high CNV score in tumor cells, lower cytotoxicity in CD8+ T cells, higher quiescence and exhaustion characteristics CD4+ T cells, compared to sensitive (PCPAs) patient. Meanwhile, the PCPAi patient showed more complex fibroblasts and tumor-associated macrophages heterogeneity. We also found the key ligand-receptor based cellular interactions, such as SPP1 and TGFβ. These results provide a research basis for us to understand the microenvironment changes and therapeutic efficacy of triple negative breast cancer after chemotherapy combined with immunotherapy.

2025-12-31 | GSE302453 | GEO

Methylation-based cellular deconvolution of triple-negative breast cancer DNA reveals prognostic immune signature

Project description:In triple negative breast cancer (TNBC), immune infiltration is now recognised as playing an important role in prognosis. DNA methylation, due to its cell-type specificity, offers a promising approach for quantifying immune cell abundance as a biomarker for risk stratification. Here, we used EpiDISH, a DNA methylation-based cellular deconvolution method, to estimate immune cell proportions from genome-wide methylation data across three independent cohorts, including TNBC patients. We show that increased immune cell percentage in TNBC patients specifically, was associated with longer disease-specific survival, highlighting the potential of DNA methylation-based estimates of cell composition for prognosis in TNBC.

2026-01-19 | GSE308164 | GEO

Gene expression profiles of TN breast tumors

Project description:Engaging the immune system promises to be key for optimal cancer therapy, especially in hard-to-treat disease such as triple-negative breast cancer (TNBC). However, the immune microenvironment remains poorly understood. Using gene expression based on laser capture microdissection, we identify three distinct tumor microenvironments associated with CD8+ T cell localization patterns and outcome in TNBC. An immunoreactive microenvironment is defined by granzyme B-positive CD8+ T cell infiltration, a type I interferon signature, tumor expression of PD-L1 and good outcome. In contrast, tumors with an immune-cold microenvironment display restriction of CD8+ T cells to tumor margins, elevated tumor expression of the immunosuppressive marker B7-H4, a signature of desmoplastic stroma and poor outcome. A third distinct immunomodulatory microenvironment associated with poor outcome is enriched for IL-17-producing cells and neutrophils, as well as stroma-restricted localisation of CD8+ T cells. These distinct immune microenvironments have implications for TNBC patient stratification for current and future therapies.

2019-02-22 | GSE88847 | GEO

Gene expression profiles of microdissected tumor epithelium and stroma from TN breast tumors

2019-02-22 | GSE88715 | GEO